Skip to main content
SpringerLink
Log in

Multidrug-Resistant Organisms: Pre-transplant Evaluation and Management

Emerging Transplant Infections

Abstract

Multidrug-resistant organisms (MDROs) cause morbidity and mortality after organ transplantation. Infection from these organisms may arise from pre-transplant colonization/infectious events, and these organisms may be donor-derived. Here we review the epidemiology, clinical manifestations, disease diagnostics, and therapeutic modalities for six common MDRO bacterial pathogens in the context of solid organ and bone marrow transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Anesi JA, Blumberg EA, Han JH, Lee DH, Clauss H, Climaco A, et al. Risk factors for multidrug-resistant organisms among deceased organ donors. Am J Transplant. 2019;19(9):2468–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Anesi JA, Blumberg EA, Abbo LM. Perioperative antibiotic prophylaxis to prevent surgical site infections in solid organ transplantation. Transplantation. 2018;102(1):21–34.

    Article  CAS  PubMed  Google Scholar 

  3. Song SH, Li XX, Wan QQ, Ye QF. Risk factors for mortality in liver transplant recipients with ESKAPE infection. Transplant Proc. 2014;46(10):3560–3.

    Article  CAS  PubMed  Google Scholar 

  4. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. McKinnell JA, Kunz DF, Chamot E, Patel M, Shirley RM, Moser SA, et al. Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol. 2012;33(7):718–24.

    Article  PubMed  Google Scholar 

  6. Van Tyne D, Gilmore MS. Friend turned foe: evolution of enterococcal virulence and antibiotic resistance. Annu Rev Microbiol. 2014;68:337–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Nellore A, Huprikar S, AST ID Community of Practice. Vancomycin-resistant Enterococcus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33:e13549.

    Article  Google Scholar 

  8. Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis. 2000;31(4):1058–65.

    Article  CAS  PubMed  Google Scholar 

  9. Okano A, Isley NA, Boger DL. Peripheral modifications of [Psi[CH2NH]Tpg(4)]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics. Proc Natl Acad Sci U S A. 2017;114(26):E5052–E61.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010;120(12):4332–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, Nathan C, et al. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med. 1998;158(10):1127–32.

    Article  CAS  PubMed  Google Scholar 

  12. Ziakas PD, Pliakos EE, Zervou FN, Knoll BM, Rice LB, Mylonakis E. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant. 2014;14(8):1887–94.

    Article  CAS  PubMed  Google Scholar 

  13. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008;455(7214):804–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42(2):195–203.

    Article  PubMed  Google Scholar 

  15. Zacharioudakis IM, Zervou FN, Ziakas PD, Rice LB, Mylonakis E. Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance. Am J Kidney Dis. 2015;65(1):88–97.

    Article  CAS  PubMed  Google Scholar 

  16. Ziakas PD, Thapa R, Rice LB, Mylonakis E. Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies. PLoS One. 2013;8(9):e75658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bashir A, Attie O, Sullivan M, Sebra R, Singh KV, Altman D, et al. Genomic confirmation of vancomycin-resistant Enterococcus transmission from deceased donor to liver transplant recipient. PLoS One. 2017;12(3):e0170449.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Russell DL, Flood A, Zaroda TE, Acosta C, Riley MM, Busuttil RW, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008;8(8):1737–43.

    Article  CAS  PubMed  Google Scholar 

  19. Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant Enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13(5):615–21.

    Article  PubMed  Google Scholar 

  20. Vydra J, Shanley RM, George I, Ustun C, Smith AR, Weisdorf DJ, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(6):764–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kang Y, Vicente M, Parsad S, Brielmeier B, Pisano J, Landon E, et al. Evaluation of risk factors for vancomycin-resistant Enterococcus bacteremia among previously colonized hematopoietic stem cell transplant patients. Transpl Infect Dis. 2013;15(5):466–73.

    CAS  PubMed  Google Scholar 

  22. Avery R, Kalaycio M, Pohlman B, Sobecks R, Kuczkowski E, Andresen S, et al. Early vancomycin-resistant Enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 2005;35(5):497–9.

    Article  CAS  PubMed  Google Scholar 

  23. Tavadze M, Rybicki L, Mossad S, Avery R, Yurch M, Pohlman B, et al. Risk factors for vancomycin-resistant Enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(10):1310–6.

    Article  CAS  PubMed  Google Scholar 

  24. Ford CD, Gazdik MA, Lopansri BK, Webb B, Mitchell B, Coombs J, et al. Vancomycin-resistant Enterococcus colonization and bacteremia and hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23(2):340–6.

    Article  PubMed  Google Scholar 

  25. Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti-Infect Ther. 2014;12(10):1221–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tenover FC, Tokars J, Swenson J, Paul S, Spitalny K, Jarvis W. Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. J Clin Microbiol. 1993;31(7):1695–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Jenkins SG, Raskoshina L, Schuetz AN. Comparison of performance of the novel chromogenic spectra VRE agar to that of bile esculin azide and Campylobacter agars for detection of vancomycin-resistant enterococci in fecal samples. J Clin Microbiol. 2011;49(11):3947–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Anderson NW, Buchan BW, Young CL, Newton DW, Brenke C, Lapsley L, et al. Multicenter clinical evaluation of VRESelect agar for identification of vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol. 2013;51(8):2758–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tan TY, Jiang B, Ng LSY. Faster and economical screening for vancomycin-resistant enterococci by sequential use of chromogenic agar and real-time polymerase chain reaction. J Microbiol Immunol Infect. 2017;50(4):448–53.

    Article  PubMed  Google Scholar 

  30. Both A, Franke GC, Mirwald N, Lutgehetmann M, Christner M, Klupp EM, et al. Two-tier approach combining molecular and culture-based techniques for optimized detection of vancomycin-resistant enterococci. Diagn Microbiol Infect Dis. 2017;89(4):253–7.

    Article  CAS  PubMed  Google Scholar 

  31. Mak A, Miller MA, Chong G, Monczak Y. Comparison of PCR and culture for screening of vancomycin-resistant Enterococci: highly disparate results for vanA and vanB. J Clin Microbiol. 2009;47(12):4136–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Satlin MJ, Walsh TJ. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: three major threats to hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2017;19(6):e12762.

    Article  CAS  Google Scholar 

  33. Zhou Q, Moore C, Eden S, Tong A, McGeer A, Mount Sinai Hospital Infection Control Team. Factors associated with acquisition of vancomycin-resistant enterococci (VRE) in roommate contacts of patients colonized or infected with VRE in a tertiary care hospital. Infect Control Hosp Epidemiol. 2008;29(5):398–403.

    Article  PubMed  Google Scholar 

  34. Harris AD, Pineles L, Belton B, Johnson JK, Shardell M, Loeb M, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA. 2013;310(15):1571–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. De Angelis G, Cataldo MA, De Waure C, Venturiello S, La Torre G, Cauda R, et al. Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(5):1185–92.

    Article  PubMed  CAS  Google Scholar 

  36. Bardossy AC, Alsafadi MY, Starr P, Chami E, Pietsch J, Moreno D, et al. Evaluation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Am J Infect Control. 2017;45(12):1369–71.

    Article  PubMed  Google Scholar 

  37. Martin EM, Russell D, Rubin Z, Humphries R, Grogan TR, Elashoff D, et al. Elimination of routine contact precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: a retrospective quasi-experimental study. Infect Control Hosp Epidemiol. 2016;37(11):1323–30.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Isenman H, Fisher D. Advances in prevention and treatment of vancomycin-resistant Enterococcus infection. Curr Opin Infect Dis. 2016;29(6):577–82.

    Article  CAS  PubMed  Google Scholar 

  39. Kodali S, Vinogradov E, Lin F, Khoury N, Hao L, Pavliak V, et al. A vaccine approach for the prevention of infections by multidrug-resistant Enterococcus faecium. J Biol Chem. 2015;290(32):19512–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Laverde D, Wobser D, Romero-Saavedra F, Hogendorf W, van der Marel G, Berthold M, et al. Synthetic teichoic acid conjugate vaccine against nosocomial Gram-positive bacteria. PLoS One. 2014;9(10):e110953.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Gearhart M, Martin J, Rudich S, Thomas M, Wetzel D, Solomkin J, et al. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clin Transpl. 2005;19(6):711–6.

    Google Scholar 

  42. Cervera C, van Delden C, Gavalda J, Welte T, Akova M, Carratala J, et al. Multidrug-resistant bacteria in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):49–73.

    Article  PubMed  Google Scholar 

  43. Stripling J, Kumar R, Baddley JW, Nellore A, Dixon P, Howard D, et al. Loss of vancomycin-resistant Enterococcus fecal dominance in an organ transplant patient with clostridium difficile colitis after fecal microbiota transplant. Open Forum Infect Dis. 2015;2(2):ofv078.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Ubeda C, Bucci V, Caballero S, Djukovic A, Toussaint NC, Equinda M, et al. Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. Infect Immun. 2013;81(3):965–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–86.

    Article  CAS  PubMed  Google Scholar 

  46. Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H. Linezolid: a promising option in the treatment of Gram-positives. J Antimicrob Chemother. 2017;72(2):354–64.

    Article  PubMed  CAS  Google Scholar 

  47. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43(2):180–7.

    Article  CAS  PubMed  Google Scholar 

  48. Chuang YC, Lin HY, Chen PY, Lin CY, Wang JT, Chen YC, et al. Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia. Clin Infect Dis. 2017;64(8):1026–34.

    Article  CAS  PubMed  Google Scholar 

  49. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother. 2014;58(2):734–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer. 2011;19(12):1969–74.

    Article  PubMed  Google Scholar 

  51. Whang DW, Miller LG, Partain NM, McKinnell JA. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother. 2013;57(10):5013–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Twilla JD, Finch CK, Usery JB, Gelfand MS, Hudson JQ, Broyles JE. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J Hosp Med. 2012;7(3):243–8.

    Article  PubMed  Google Scholar 

  53. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther. 2010;32(10):1713–9.

    Article  CAS  PubMed  Google Scholar 

  54. Britt NS, Potter EM, Patel N, Steed ME. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients. Clin Infect Dis. 2015;61(6):871–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Mercuro NJ, Davis SL, Zervos MJ, Herc ES. Combatting resistant enterococcal infections: a pharmacotherapy review. Expert Opin Pharmacother. 2018;19(9):1–14.

    Google Scholar 

  56. Perez F, Salata RA, Bonomo RA. Current and novel antibiotics against resistant Gram-positive bacteria. Infect Drug Resist. 2008;1:27–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Perri MB, Hershberger E, Ionescu M, Lauter C, Zervos MJ. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis. 2002;42(4):269–71.

    Article  CAS  PubMed  Google Scholar 

  58. Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother. 1999;43(2):211–7.

    Article  CAS  PubMed  Google Scholar 

  59. Lewis JD, Enfield KB, Cox HL, Mathers AJ, Sifri CD. A single-center experience with infections due to daptomycin-nonsusceptible Enterococcus faecium in liver transplant recipients. Transpl Infect Dis. 2016;18(3):341–53.

    Article  CAS  PubMed  Google Scholar 

  60. Moise PA, Sakoulas G, McKinnell JA, Lamp KC, DePestel DD, Yoon MJ, et al. Clinical outcomes of daptomycin for vancomycin-resistant Enterococcus bacteremia. Clin Ther. 2015;37(7):1443–53 e2.

    Article  CAS  PubMed  Google Scholar 

  61. Bi R, Qin T, Fan W, Ma P, Gu B. The emerging problem of linezolid-resistant enterococci. J Glob Antimicrob Resist. 2017;13:11–9.

    Article  PubMed  Google Scholar 

  62. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A. 2002;99(11):7687–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Huang YH, Tseng SP, Hu JM, Tsai JC, Hsueh PR, Teng LJ. Clonal spread of SCCmec type IV methicillin-resistant Staphylococcus aureus between community and hospital. Clin Microbiol Infect. 2007;13(7):717–24.

    Article  CAS  PubMed  Google Scholar 

  65. Paterson GK, Harrison EM, Holmes MA. The emergence of mecC methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2014;22(1):42–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Paulsen G, Blum S, Danziger-Isakov L. Epidemiology and outcomes of pretransplant methicillin-resistant Staphylococcus Aureus screening in pediatric solid organ transplant candidates. Pediatr Transplant. 2018;22:e13246.

    Article  CAS  Google Scholar 

  67. Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Meta-analysis of methicillin-resistant Staphylococcus aureus colonization and risk of infection in dialysis patients. J Am Soc Nephrol. 2014;25(9):2131–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Koval CE, Rakita R, ASTIDCo P. Ventricular assist device related infections and solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):348–54.

    Article  PubMed  Google Scholar 

  69. Miles-Jay A, Podczervinski S, Stednick ZJ, Pergam SA. Evaluation of routine pretransplantation screening for methicillin-resistant Staphylococcus aureus in hematopoietic cell transplant recipients. Am J Infect Control. 2015;43(1):89–91.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Senn L, Basset P, Nahimana I, Zanetti G, Blanc DS. Which anatomical sites should be sampled for screening of methicillin-resistant Staphylococcus aureus carriage by culture or by rapid PCR test? Clin Microbiol Infect. 2012;18(2):E31–3.

    Article  CAS  PubMed  Google Scholar 

  71. Giersing BK, Dastgheyb SS, Modjarrad K, Moorthy V. Status of vaccine research and development of vaccines for Staphylococcus aureus. Vaccine. 2016;34(26):2962–6.

    Article  CAS  PubMed  Google Scholar 

  72. Kullar R, Vassallo A, Turkel S, Chopra T, Kaye KS, Dhar S. Degowning the controversies of contact precautions for methicillin-resistant Staphylococcus aureus: a review. Am J Infect Control. 2016;44(1):97–103.

    Article  PubMed  Google Scholar 

  73. Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis. 2002;35(12):1513–9.

    Article  PubMed  Google Scholar 

  74. Pereira MR, Rana MM, AICo P. Methicillin-resistant Staphylococcus aureus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33:e13611.

    Article  Google Scholar 

  75. Gebreselassie HM, Lo Priore E, Marschall J. Effectiveness of meticillin-resistant Staphylococcus aureus decolonization in long-term haemodialysis patients: a systematic review and meta-analysis. J Hosp Infect. 2015;91(3):250–6.

    Article  CAS  PubMed  Google Scholar 

  76. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984;14(Suppl D):7–18.

    Article  CAS  PubMed  Google Scholar 

  77. Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M. Daptomycin. J Antimicrob Chemother. 2018;73(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  78. Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60(10):5841–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis. 2014;58(Suppl 1):S20–7.

    Article  CAS  PubMed  Google Scholar 

  80. Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2017;23(10):697–703.

    Article  CAS  PubMed  Google Scholar 

  81. Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, et al. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018;556(7699):103–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients – review of the literature from a clinical perspective. Crit Rev Microbiol. 2016;42(1):1–16.

    Article  CAS  PubMed  Google Scholar 

  83. Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8(4):391–402.

    Article  CAS  PubMed  Google Scholar 

  84. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460–9.

    Article  PubMed  CAS  Google Scholar 

  86. Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis. 2010;12(1):87–93.

    Article  CAS  PubMed  Google Scholar 

  87. Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti-Infect Ther. 2013;11(4):383–93.

    Article  CAS  PubMed  Google Scholar 

  88. Karampatakis T, Antachopoulos C, Tsakris A, Roilides E. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data. Eur J Clin Microbiol Infect Dis. 2018;37(7):1211–20.

    Article  PubMed  Google Scholar 

  89. Massa E, Michailidou E, Agapakis D, Papadopoulos S, Tholioti T, Aleuroudis I, et al. Colonization and infection with extensively drug resistant gram-negative bacteria in liver transplant recipients. Transplant Proc. 2019;51(2):454–6.

    Article  CAS  PubMed  Google Scholar 

  90. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–106.

    Article  PubMed  Google Scholar 

  91. Lubbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42(2):309–16.

    Article  CAS  PubMed  Google Scholar 

  92. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14(2):198–205.

    Article  CAS  PubMed  Google Scholar 

  93. Ariza-Heredia EJ, Patel R, Blumberg EA, Walker RC, Lewis R, Evans J, et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis. 2012;14(3):229–36.

    Article  CAS  PubMed  Google Scholar 

  94. Goldberg E, Bishara J, Lev S, Singer P, Cohen J. Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report. Transpl Infect Dis. 2012;14(3):296–9.

    Article  CAS  PubMed  Google Scholar 

  95. Mularoni A, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, et al. Outcome of transplantation using organs from donors infected or colonized with carbapenem-resistant gram-negative bacteria. Am J Transplant. 2015;15(10):2674–82.

    Article  CAS  PubMed  Google Scholar 

  96. Shoham S, Shah PD. Impact of multidrug-resistant organisms on patients considered for lung transplantation. Infect Dis Clin N Am. 2013;27(2):343–58.

    Article  Google Scholar 

  97. Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50(2):282–8.

    Article  CAS  PubMed  Google Scholar 

  98. Kossow A, Kampmeier S, Willems S, Berdel WE, Groll AH, Burckhardt B, et al. Control of multidrug-resistant Pseudomonas aeruginosa in allogeneic hematopoietic stem cell transplant recipients by a novel bundle including remodeling of sanitary and water supply systems. Clin Infect Dis. 2017;65(6):935–42.

    Article  PubMed  Google Scholar 

  99. Giannella M, Bartoletti M, Morelli MC, Tedeschi S, Cristini F, Tumietto F, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. Am J Transplant. 2015;15(6):1708–15.

    Article  CAS  PubMed  Google Scholar 

  100. Huprikar SCL, Pierrotti LC, Nellore A, Madan R, Garcia-Diaz J, Jacobs S, Lee D, Trindade Clemente W, Alangaden G, et al. Outcomes associated with carbapenem-resistant Enterobacteriaceae infection after solid organ transplantation in a multicenter study. Program and abstracts of the 16th American Transplant congress, American Society of Transplant Surgeons and the American Society of Transplantation. Boston. 2016.

    Google Scholar 

  101. Freire MP, Villela Soares Oshiro IC, Bonazzi PR, Pierrotti LC, de Oliveira LM, Machado AS, et al. Surveillance culture for multidrug-resistant gram-negative bacteria: performance in liver transplant recipients. Am J Infect Control. 2017;45(3):e40–e4.

    Article  PubMed  Google Scholar 

  102. Banerjee R, Humphries R. Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8(4):427–39.

    Article  CAS  PubMed  Google Scholar 

  103. Rodrigues Dos Santos BG, Amaral ES Jr, Fernandes PF, Oliveira CM, Rodrigues JL, Perdigao Neto LV, et al. Urinary tract infections and surgical site infections due to carbapenem-resistant Enterobacteriaceae in renal transplant. Transplant Proc. 2016;48(6):2050–5.

    Article  CAS  PubMed  Google Scholar 

  104. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54(1):526–9.

    Article  CAS  PubMed  Google Scholar 

  105. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56(11):5744–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729–40.

    Article  CAS  PubMed  Google Scholar 

  107. Zhang Y, Lin X, Bush K. In vitro susceptibility of beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot (Tokyo). 2016;69(8):600–4.

    Article  CAS  Google Scholar 

  108. de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271–89.

    Article  CAS  PubMed  Google Scholar 

  110. Epstein L, Hunter JC, Arwady MA, Tsai V, Stein L, Gribogiannis M, et al. New Delhi metallo-beta-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA. 2014;312(14):1447–55.

    Article  PubMed  CAS  Google Scholar 

  111. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA

    Anoma Nellore & Rachael A. Lee

Authors
  1. Anoma Nellore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachael A. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anoma Nellore .

Editor information

Editors and Affiliations

  1. Miller School of Medicine, University of Miami, Miami, FL, USA

    Michele I. Morris

  2. Massachusetts General Hospital, Harvard University, Boston, MA, USA

    Camille Nelson Kotton

  3. Duke University, Durham, NC, USA

    Camille Wolfe

Section Editor information

  1. Infectious Diseases Division, Harvard University Medical School, Boston, MA, USA

    Camille Nelson Kotton

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nellore, A., Lee, R.A. (2020). Multidrug-Resistant Organisms: Pre-transplant Evaluation and Management. In: Morris, M., Kotton, C., Wolfe, C. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-01751-4_8-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-01751-4_8-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-01751-4

  • Online ISBN: 978-3-030-01751-4

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Multidrug-Resistant Organisms: Pre-transplant Evaluation and Management
    Published:
    30 November 2020

    DOI: https://doi.org/10.1007/978-3-030-01751-4_8-2

  2. Original

    Multidrug-Resistant Organisms: Pre-transplant Evaluation and Management
    Published:
    27 January 2020

    DOI: https://doi.org/10.1007/978-3-030-01751-4_8-1

Search

Navigation